ID   Mero-95
AC   CVCL_2597
SY   MERO95
DR   cancercelllines; CVCL_2597
DR   Cell_Model_Passport; SIDM01906
DR   DepMap; ACH-001562
DR   ECACC; 09100108
DR   Wikidata; Q54905217
RX   PubMed=2474517;
RX   PubMed=25902174;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~30 hours (ECACC=09100108).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap=ACH-001562; ECACC=09100108
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 14,17
ST   D21S11: 28,30
ST   D3S1358: 14,15
ST   D5S818: 11,14
ST   D7S820: 7,9
ST   D8S1179: 11,15
ST   FGA: 21,23
ST   Penta D: 12,13
ST   Penta E: 11,12
ST   TH01: 6
ST   TPOX: 8,12
ST   vWA: 18,19
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 19
//
RX   PubMed=2474517; DOI=10.1002/ijc.2910440212;
RA   Versnel M.A., Bouts M.J., Hoogsteden H.C., van der Kwast T.H.,
RA   Delahaye M., Hagemeijer A.;
RT   "Establishment of human malignant mesothelioma cell lines.";
RL   Int. J. Cancer 44:256-260(1989).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//